Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Research  




2 References  













RO4929097







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

RO4929097
Identifiers

  • 2,2-Dimethyl-N-[(10S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-10-yl]-'N′-(2,2,3,3,3-pentafluoropropyl)propanediamide

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H20F5N3O3
Molar mass469.412 g·mol−1
3D model (JSmol)

  • O=C1Nc2ccccc2c2c(C1NC(=O)C(C(=O)NCC(C(F)(F)F)(F)F)(C)C)cccc2

  • InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1

  • Key:OJPLJFIFUQPSJR-INIZCTEOSA-N

RO4929097 (RG-4733) is a gamma secretase inhibitor being studied as an anti-cancer drug.[1] Targeting gamma secretase inhibits NOTCH signaling, which is upregulated in many forms of cancer.[2] The drug was initially developed by Roche for the treatment of Alzheimer's disease, but current research focuses on cancer.[3] Production was halted in 2010, but began again in 2014.[4]

Research[edit]

Over 35 phase I and II clinical trials have been performed, but no phase III trials have yet commenced.[5] Phase II studies have investigated the use of RO4929097 in ovarian cancer,[6] renal cell carcinoma in patients that were unsuccessful on anti-VEGF treatments,[7] metastatic pancreatic cancer,[8] advanced brain tumors,[9] and relapsed non-small cell lung cancer.[10]

Other planned clinical trials were terminated, because the drug became unavailable.[11]

References[edit]

  1. ^ Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF (October 2009). "Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties". Cancer Research. 69 (19): 7672–80. doi:10.1158/0008-5472.CAN-09-1843. PMC 5260798. PMID 19773430.
  • ^ "Gamma-secretase/Notch signalling pathway inhibitor RO4929097". NCI Drug Dictionary. National Cancer Institute.
  • ^ "RO4929097". IUPHAR/BPS Guide to PHARMACOLOGY.
  • ^ "RG 4733". AdisInsight. Springer Nature Switzerland AG.
  • ^ "Search for: RO4929097 - List Results - ClinicalTrials.gov".
  • ^ Clinical trial number NCT01175343 for "RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01141569 for "A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01232829 for "Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01122901 for "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01070927 for "An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01216787 for "RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery" at ClinicalTrials.gov

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=RO4929097&oldid=1138419165"
    Category: 
    ●Experimental cancer drugs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 9 February 2023, at 15:52 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki